BriaCell Therapeutics Stock Scheduled to Reverse Split on Wednesday, January 29th (NASDAQ:BCTX)

BriaCell Therapeutics Corp. (NASDAQ:BCTXFree Report)’s stock is set to reverse split on Wednesday, January 29th. The 1-15 reverse split was announced on Friday, January 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, January 28th.

BriaCell Therapeutics Stock Performance

Shares of BCTX opened at $0.39 on Friday. The company has a market cap of $17.02 million, a price-to-earnings ratio of -0.43 and a beta of 1.55. The stock has a fifty day moving average price of $0.68 and a two-hundred day moving average price of $0.75. BriaCell Therapeutics has a 52-week low of $0.37 and a 52-week high of $4.61.

BriaCell Therapeutics (NASDAQ:BCTXGet Free Report) last announced its earnings results on Monday, December 16th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). As a group, research analysts predict that BriaCell Therapeutics will post -1.01 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of BriaCell Therapeutics in a research report on Thursday, December 12th.

Get Our Latest Analysis on BriaCell Therapeutics

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. purchased a new stake in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTXFree Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics as of its most recent SEC filing. 15.42% of the stock is owned by hedge funds and other institutional investors.

BriaCell Therapeutics Company Profile

(Get Free Report)

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.

See Also

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.